申请人:C&C Research Laboratories
公开号:EP3461825A1
公开(公告)日:2019-04-03
The present invention relates to novel heterocyclic compounds useful in preparing drugs for treatment of diseases associated with various functions of the histamine 4 receptor. Especially, the said drugs are useful for treatment of inflammatory diseases, allergy, pain, nasal polyps, rhinitis, chronic sinusitis, nasal congestion, nasal itch, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis, eczema, pruritus, itchy skin, urticaria, idiopathic chronic urticaria, scleroderma, conjunctivitis, keratoconjunctivitis, ocular inflammation, dry eye, cardiac dysfunction, arrhythmia, atherosclerosis, multiple sclerosis, inflammatory bowel disease (including colitis, Crohn's disease, ulcerative colitis), inflammatory pain, neuropathic pain, osteoarthritic pain, autoimmune thyroid disease, immune-mediated (also known as type I) diabetes, lupus, post-operative adhesions, vestibular disorders and cancer.
本发明涉及新型
杂环化合物,可用于制备治疗与
组胺 4 受体各种功能相关疾病的药物。特别是,所述药物可用于治疗炎症性疾病、过敏、疼痛、鼻息肉、鼻炎、慢性鼻窦炎、鼻塞、鼻痒、哮喘、慢性阻塞性肺病、类风湿性关节炎、特应性皮炎、牛皮癣、湿疹、瘙痒症、皮肤瘙痒、荨麻疹、特发性慢性荨麻疹、硬皮病、结膜炎、角结膜炎、眼部炎症、干眼症、心脏功能障碍、心律失常、眼部炎症、干眼症、心脏功能障碍、心律失常、动脉粥样硬化、多发性硬化、炎症性肠病(包括结肠炎、克罗恩病、溃疡性结肠炎)、炎症性疼痛、神经性疼痛、骨关节炎性疼痛、自身免疫性甲状腺疾病、免疫介导型(又称 I 型)糖尿病、红斑狼疮、术后粘连、前庭失调和癌症。